Anzeige
Mehr »
Samstag, 15.11.2025 - Börsentäglich über 12.000 News
Trump. Zölle. Craig Parry. Vizsla Copper wird zur strategisch wichtigsten Kupferaktie Nordamerikas
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14156 | ISIN: GB00BYMT0J19 | Ticker-Symbol: LIA
Tradegate
13.11.25 | 17:11
48,000 Euro
+0,42 % +0,200
1-Jahres-Chart
LIVANOVA PLC Chart 1 Jahr
5-Tage-Chart
LIVANOVA PLC 5-Tage-Chart
RealtimeGeldBriefZeit
47,40047,80014.11.
47,20048,00014.11.

Aktuelle News zur LIVANOVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoLivaNova outlines plans for future growth at investor day event2
MiLivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day2
MiLivaNova peilt bis 2030 hohes einstelliges Umsatzwachstum an12
MiLivaNova outlines 2030 targets with high-single-digit revenue growth1
MiLivaNova PLC: LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day316Provides 2030 Targets for Revenue and EPS Growth LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic...
► Artikel lesen
07.11.Needham reiterates Buy rating on Livanova stock ahead of Investor Day5
LIVANOVA Aktie jetzt für 0€ handeln
05.11.LivaNova raises 2025 revenue growth outlook to 10.5% amid strong cardiopulmonary expansion and Essenz China launch2
05.11.Stifel raises Livanova stock price target to $65 on strong Q3 results10
05.11.LivaNova PLC - 10-Q, Quarterly Report-
05.11.LivaNova beats Street in Q3, raises guidance again7
05.11.LivaNova PLC Non-GAAP EPS of $1.11 beats by $0.19, revenue of $357.8M beats by $15.08M1
05.11.LivaNova PLC - 8-K, Current Report-
23.10.LivaNova PLC: LivaNova to Present at Wolfe Research Healthcare Conference in November232LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsburg, Chief Financial Officer, will present...
► Artikel lesen
08.10.LivaNova PLC: LivaNova to Announce Third-Quarter 2025 Results220LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5, 2025, at 1 p.m. London time (8 a.m....
► Artikel lesen
07.10.LivaNova PLC: LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting237Company studies continue to show durability and retention of benefits for patients receiving proximal hypoglossal nerve stimulation for moderate to severe obstructive sleep apnea LivaNova PLC (Nasdaq:...
► Artikel lesen
01.10.Doximity, LivaNova downgraded as Goldman Sachs reviews MedTech and Health IT coverage4
01.10.Goldman Sachs stuft Livanova wegen verlangsamter Wachstumsaussichten auf "Neutral" herab2
01.10.Goldman Sachs downgrades Livanova stock to Neutral on slowing growth outlook2
19.09.Research and Markets: Europe Refractory Epilepsy Treatment Research and Forecast Report 2025-2035 | Competitive Analysis of UCB, Novartis, LivaNova, GSK, and Biocodex - ResearchAndMarkets.com666The "Europe Refractory Epilepsy Treatment Market: Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering. The Europe refractory epilepsy treatment market is...
► Artikel lesen
10.09.LivaNova auf Morgan-Stanley-Konferenz: Expansionskurs in der Neuromodulation2
Weiter >>
63 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1